Product

Portfolio Intelligence Portside Congress trades Super-investors Economic calendar Earnings calendar Pricing

Company

About FAQs Contact Create account

Legal

Privacy Terms Portside rules

AARD

Aardvark Therapeutics, Inc.

COMMON STOCK · NASDAQ

Price and daily changeSign in

Earnings12 Nov 2026

52-week rangeSign in

Loading evidence for AARD

Day range

Market cap: Sign in
Volume: Sign in
Beta: Sign in
Shares float: Sign in
Short interest: 2.33%
P/E (fwd): Sign in
PEG (fwd): Sign in
Rev growth (fwd): Sign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Create free account

Overview Statistics Statements Dividends🔒Momentum🔒Quant🔒Fair Value🔒Earnings Analysts🔒Insiders Smart Money Options🔒Insights🔒

Trading information

Beta: Sign in
Shares outstandingAs of 2026-07-31 · filed common shares: 21.88M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 7.54%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 2.33%
Short ratioDays to cover, as published by FINRA: 3.77
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 60.60%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 47.10%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Avg volume (3 months)

Profitability

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -66.02%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -61.06%

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): —
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-3.22

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $73.84M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $677.00K
Debt / equityas of Jun 26: 0.91%
Current ratioas of Jun 26: 12.63
Quick ratio: —
Operating cash flowTTM to Jun 26: -$69.40M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$69.41M
TTM revenue / diluted share: —

AARD stock Statistics — Aardvark Therapeutics, Inc. filings, insiders & smart money · Instaport